Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have revolutionized the treatment landscape of the non-small cell lung cancers (NSCLCs) which harbor EGFR sensitizing mutations over the past decades. Here, EGFR is linked to non-small cell lung carcinoma.